Nasdaq grants HeartSciences extension to Sept 15, 2025 for equity rule; Q3 cash $2.6M, equity $1.8M

HeartSciences Inc.

Nasdaq extension to Sept 15, 2025 to regain $2.5M minimum stockholders' equity; delisting if not met by Oct 31, 2025 10-Q filing.
Q3 FY2025 ended Jan 31, 2025: no revenue, cash $2.6M, shareholders' equity $1.8M.
MyoVista wavECG device clinical validation nearing completion; FDA submission expected first half calendar 2025.
Low ejection fraction algorithm pre-validation with Rutgers; aim for FDA submission in second half 2025.
CMS 2025 OPPS final rule includes AI-ECG reimbursement effective Jan 2025, enabling payment upon commercial launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.